GlassScriptPhysician profile
Catherine L Sullivan
NPI 1548256100
$6,621.67
in general payments reported to CMS, 2019-2025
24 companies · $805 in 2025
The $805 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $433 · 2021: $878 · 2022: $1,455 · 2023: $985 · 2024: $1,620 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.20 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,577.37 | 2019-2025 | Evenity, Otezla, Enbrel |
| Janssen Biotech, INC. | $659.12 | 2020-2025 | Tremfya, Simponi Aria |
| Novo Nordisk INC | $436.86 | 2021-2023 | Wegovy |
| Averitas Pharma INC. | $376.07 | 2024 | Qutenza |
| Radius Health, INC. | $357.85 | 2019-2024 | Tymlos |
| Pfizer INC. | $333.75 | 2022-2025 | |
| Horizon Therapeutics Plc | $245.40 | 2019-2022 | |
| Glaxosmithkline, LLC. | $213.13 | 2019-2024 | Benlysta, Nucala |
| Ucb, INC. | $207.77 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $195.45 | 2022-2025 | Mounjaro, Taltz |
| Mallinckrodt Hospital Products INC. | $184.04 | 2021-2023 | Acthar |
| Abbvie INC. | $152.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $130.55 | 2020-2021 | |
| Grt US Holding, INC. | $125.30 | 2022 | |
| Ibsa Pharma INC. | $103.34 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $100.52 | 2024 | Crysvita |
| Novartis Pharmaceuticals Corporation | $46.88 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $39.52 | 2022-2023 | Gvoke Hypopen |
| Organon LLC | $37.19 | 2024 | |
| Sobi, INC | $31.63 | 2019 | |
| Antares Pharma, INC. | $20.05 | 2021 | |
| Millicent US INC | $17.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.98 | 2023 | Cyltezo |
| Avion Pharmaceuticals | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.